In PLOS this week: reference bias effects in ancient genomics, tsetse fly genetic diversity, and more.
In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
The test measures hepatitis B viral DNA and is intended to be used to assess prognosis and response to antiviral therapies.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
Qiagen's partnership and merger agreement with NeuMoDx may help it compete with high-volume molecular testing vendors such as Abbott, Hologic, and Roche.
Researchers integrated results from a pathogen-host association study with available clinical data to find variants influencing both infection responses and other disease risks.
Several companies will receive grants to develop hepatitis C molecular point-of-care and core antigen diagnostic assays.
The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.